• Contact Us
  • Sign Up
  • TWITTER
Microbiome Times Magazine
  • Human Health
  • Animal Health
  • Phytobiome
  • Finance
    • Finance Articles
    • Microbiome Stocks
  • Drug Database
    • About
    • Login/ Register
  • Issue Archive
  • Advertise

Editor’s Choice

Editor's Choice

Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy

May 6, 2020 Staff Editor

Today, Rebiotix and Ferring Pharmaceuticals announced positive preliminary findings from their ongoing pivotal Phase 3 trial of the investigational microbiome-based treatment, RBX2660. These preliminary positive efficacy findings mark an important milestone, advancing RBX2660 in its […]

Editor's Choice

Microbiome after coronavirus: Investing in the power of microbes

April 30, 2020 Luis Gosálbez

The COVID-19 crisis is causing immense suffering and an appalling death toll. It has also dramatically impacted our personal and professional lives, and individuals, businesses and investors can’t wait to get back to normalcy. However, […]

Editor's Choice

Until next Probiota, savor the learnings of Probiota Dublin 2020

April 30, 2020 Nina Vinot

Probiota is set with the ambition to connect business and science of the microbiome space, build community, start conversations and inspire innovation, as very well expressed by Nathan Gray from William Reed. Probiota this year […]

Editor's Choice

Validity Attack on US Patent for Bifidobacetrium Combo-Therapy: What can we learn?

April 29, 2020 Craig Thomson, Dr Leena Contarino, Dr Lauris Kemp, David Resnick and Mark FitzGerald

Although the April 15, 2020 decision of the U.S. Patent Trial and Appeal Board (PTAB) was to invalidate The University of Chicago’s US microbiome patent, much can be learned and some positive notes echo from […]

Editor's Choice

The Lactobacillus taxonomy change has arrived! What do you need to know?

April 21, 2020 Nina Vinot and Marco Pane

Taxonomy is the branch of science that classifies and names organisms. Lactobacillus were first described in 1901 with Lactobacillus delbrueckii, a species indispensable in yogurt, and grew exponentially since the beginning of the 21stcentury thanks to […]

Editor's Choice

A common gut microbe secretes a carcinogen

April 4, 2020 Staff Editor

Cancer mutations can be caused by common gut bacteria carried by many people. This was demonstrated by researchers from the Hubrecht Institute (KNAW) and Princess Máxima Center in Utrecht, the Netherlands. By exposing cultured human […]

Editor's Choice

The Microbiome Biotech Landscape: An Analysis of the Pharmaceutical Pipeline

March 26, 2020 Luis Gosálbez

Introduction The microbiome is one of the hottest areas in biotechnology, as countless studies have linked its composition and activity with human disease1,2, especially in illnesses of poorly understood mechanisms, with high medical unmet needs. […]

Editor's Choice

FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms

March 13, 2020 Staff Editor

The Food and Drug Administration (FDA) is informing health care providers and patients of the potential risk of serious or life-threatening infections with the use of fecal microbiota for transplantation (FMT). The agency is now aware […]

Editor's Choice

Securing Commercial Advantage through Innovations in Microbiome Therapeutic Production

March 4, 2020 Craig Thomson and Dr Leena Contarino

Introduction With every article of the Microbiome Times, one sees the therapeutic microbiome industry edging ever-closer to full commercialisation of their products. Understandably, much of the focus has been on the challenging process of demonstrating […]

Editor's Choice

Dr. Georg Gerber on the computational approaches that will enable new microbiome diagnostics and therapeutics

February 12, 2020 Kristina Campbell

Many different chronic diseases have been associated with distinct gut microbiome ‘signatures’, but what has proved challenging to date is the translation of the compositional and functional microbiome differences into novel diagnostics and therapeutics. Moving […]

Editor's Choice

Non-living microbiome therapeutics: European organisation strives to bring regulatory challenges for these drug products into focus

February 3, 2020 Kristina Campbell

The human microbiome is often described as an ‘ecosystem’, evoking a complex collection of organisms that are alive and dynamic. So when considering strategies for modulating the human microbiome to prevent or treat a disease, […]

Posts navigation

« 1 2 3 … 8 »

Microbiome-based Diagnostics & Biomarkers: Free Market Report

Sign Up to Free Newsletter

The Microbiome Drug Database

The Microbiome Drug Landscape report: Promising clinical performance and signs of a maturing industry

Market Reports
October 26, 2020
Abstract Year 2020 has been a pivotal year for microbiome-focused drug companies. This year the industry saw the release of two much-anticipated Phase 3 studies, which showed positive results and set the stage for new [...]

Editor’s Choice

  • Fecal transplant turns cancer immunotherapy non-responders into responders
    February 10, 2021
  • Why microbiota samples should be collected in all clinical trials?
    January 26, 2021
  • Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19
    January 20, 2021
  • Poor gut health connected to severe COVID-19, new review shows
    January 18, 2021
  • First Published Clinical Trial Using Live Biotherapeutic Candidate In COVID-19 Patients Suggests Role In Improving Outcomes
    September 25, 2020
Categories
  • Animal Health
  • Editor's Choice
  • Finance
  • Lallemand Health Solutions
  • Market Reports
  • Pharma & Human Health
  • Phytobiome & Environment
  • Premium Content
  • Reports
  • Sponsored Content
  • Uncategorized
  • Video
  • Webinar
sign up

Sign up to the Microbiome Times newsletter